retatrutide clinical trials safety efficacy Lilly's triple agonist achieves 16.8% weight loss in phase 3 trial Retatrutide UK: Clinical Progress, Expected
Description
At 10mg/mL, doses above 10mg exceed it
More specifically, the 200mg group saw a 2.4% reduction, while the 400mg and 800mg groups experienced reductions of 1.9% and 1.7%, respectively
Cancel via account dashboard or email [email protected]
Conclusions Our findings demonstrate that individual or dual agonism of GLP-1R/GIPR has no direct actions in hepatocytes or HSCs, which might suggest that the effects of dual agonism on liver function are mediated by the reduction of weight loss and enhancement in insulin sensitivity
Mol Metab (2017) 6(10):13219
"I had a friend, and she could get it for me, she explained during an episode of her Dream On with Lottie Moss podcast
